THE JENEX CORPORATION

Cold Sore Prevention Device in Final Stages of Design

July 16, 2003

For Immediate Release

THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), Michael Jenkins, President and CEO of Jenex announces that 71,500 common shares of the Corporation will be issued at a deemed price of $0.39 per common share, which represents a 70 percent premium to the current share price, to Web Design Associates Inc., of Akron, Ohio as consideration for the completion of the engineering and design work for the Corporation’s patented cold sore prevention product. The total value of the debt settlement is $20,500 USD. The proposed transaction is arms-length. The transaction is subject to TSX Venture Exchange approval and the shares will be subject to a four-month hold period from the date of issue. Management of the Corporation believes this transaction with Web underscores their belief in the long term growth prospects of the Corporation, and demonstrates a strong vote of support for its therapeutic cold sore device.

The Corporation anticipates market distribution in Canada of its “Cold Sore Prevention Device” product in the first quarter of 2004.

ABOUT THE JENEX CORPORATION

The Corporation has proven that its patented technology is effective against HSV-1, the herpes virus that causes cold sores. In 2000, the Corporation received approval to make the following claim in Canada: “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort.  Also helps alleviate the embarrassment that typically is associated with herpes labialis (cold sore) out breaks.”

Between 20% and 40% of the population age twelve and over experience two or more cold sores per year.  Jenex has the only product approved for the prevention of cold sores.

                                                     “Prevention is the Solution”

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.  Certain information included in this press release is forward-looking and is subject to important risks and uncertainties.  The results or events predicted in these statements may differ materially from actual results or events.

For more information please contact:

The Jenex Corporation

207 – 940 Sheldon Court

Burlington, Ontario

L7L 5K6

Michael A. Jenkins, President

Telephone:  (905) 632-3830

Facsimile:   (905) 632-3774

Email:  jenex@sprint.ca

www.jenexcorp.com .